Koch Andreas M E, Rauh Manfred, Zink Stefan, Singer Helmut
Paediatric Cardiology, Department of Paediatrics and Adolescent Medicine, University of Erlangen-Nürnberg, Germany.
Acta Paediatr. 2006 Jul;95(7):805-9. doi: 10.1080/08035250500466647.
B-type natriuretic peptide (BNP) and the N-terminal fragment of proBNP (NT-proBNP) seem to be useful diagnostic tools also in children with cardiac disease. Recent data suggest that plasma levels of both peptides show different patterns from infancy to adolescence.
To investigate the relationship of BNP and NT-proBNP in children and adolescents according to age.
In 46 individuals without cardiac disease (22 males, 24 females, aged 0.4-17.5 years) and 30 patients with congenital heart disease (17 males, 13 females, aged 0.2-18.4 years), plasma levels of BNP and NT-proBNP were measured in the same sample (triage BNP assay, Biosite and Elecsys NT-proBNP assay, Roche Diagnostics).
The range of BNP plasma levels was 5-32 pg/ml in individuals without heart disease and 5-1300 pg/ml in the patient group, the range of NT-proBNP was 10-298 pg/ml and 30-18,966 pg/ml, respectively. In both groups, the ratio NT-proBNP/BNP decreased with increasing age (P<0.001).
Although proBNP is cleaved into the two fragments NT-proBNP and BNP, there is a decreasing ratio of NT-proBNP/BNP with increasing age caused probably by age-dependent differences in the metabolic clearance of both peptides. This has to be considered in comparison studies on BNP and NT-proBNP regarding their benefit to paediatric cardiology.
B型利钠肽(BNP)和氨基末端脑钠肽前体(NT-proBNP)似乎也是诊断儿童心脏病的有用工具。最近的数据表明,这两种肽的血浆水平从婴儿期到青春期呈现出不同的模式。
根据年龄调查儿童和青少年中BNP与NT-proBNP的关系。
对46名无心脏病个体(22名男性,24名女性,年龄0.4 - 17.5岁)和30名先天性心脏病患者(17名男性,13名女性,年龄0.2 - 18.4岁),在同一样本中测量BNP和NT-proBNP的血浆水平(采用Biosite公司的triage BNP检测法和罗氏诊断公司的Elecsys NT-proBNP检测法)。
无心脏病个体的BNP血浆水平范围为5 - 32 pg/ml,患者组为5 - 1300 pg/ml;NT-proBNP的范围分别为10 - 298 pg/ml和30 - 18,966 pg/ml。在两组中,NT-proBNP/BNP比值均随年龄增长而降低(P<0.001)。
尽管脑钠肽前体被裂解为NT-proBNP和BNP两个片段,但NT-proBNP/BNP比值随年龄增长而降低,这可能是由于两种肽的代谢清除存在年龄依赖性差异所致。在关于BNP和NT-proBNP对儿科心脏病学益处的比较研究中必须考虑这一点。